A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

NCT07671391 on ClinicalTrials.gov · last registry update 2026-06-26

Registered but not yet open, with 60 participants planned. Due to report July 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: The percentage change in lean body mass. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Shanghai Zhongshan Hospital
Sponsor type: Other
Enrollment: 60
Started: 2026-08
Primary completion: 2027-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The percentage change in lean body mass

Conditions studied

Obesity Adult Onset

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.